1 citations
,
July 2016 in “PubMed” This study found that 5% minoxidil topical foam used once daily for 24 weeks was well tolerated and significantly improved hair regrowth and scalp coverage in women with female pattern hair loss compared to vehicle foam.
7 citations
,
June 2000 in “Journal of the American Academy of Dermatology” This study found that betamethasone valerate in a foam vehicle has comparable total coverage to traditional topical corticosteroid vehicles, despite less coverage per unit of foam.
This abstract introduces TrichoFoam™, a new foaming vehicle for compounding pharmacies, designed to be a gentle, non-irritating option for alopecia treatment, acknowledging that current topical treatments are limited and oral products may cause adverse effects.
December 2024 in “PubMed” This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.
4 citations
,
June 2013 in “PubMed” This study found that minoxidil in Espumil Foam Base remains stable for at least 90 days when stored at room temperature and protected from light.